Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center

Introduction: Biologic drugs have dramatically improved severe eosinophilic asthma (SEA) outcomes. Our aim was to evaluate the long-term efficacy of biological therapy in SEA in a real-life setting and to identify the predictors for switching to another biological drug in patients with poor asthma c...

Full description

Bibliographic Details
Main Authors: Paolo Solidoro, Stefania Nicola, Irene Ridolfi, Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Enrico Heffler, Diego Bagnasco, Filippo Patrucco, Fulvia Ribolla, Caterina Bucca, Giovanni Rolla, Carlo Albera, Luisa Brussino
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Biomedicines
Subjects:
severe eosinophilic asthma
biologics
T2-high asthma
SANI registry
IL-5
IL-4
Online Access:https://www.mdpi.com/2227-9059/10/2/200

Internet

https://www.mdpi.com/2227-9059/10/2/200

Similar Items